Global Antibody Drug Conjugates Market — Opportunity Analysis, 2016–2024
In terms of marketing, three antibody drug conjugates have received regulatory approval. The U.S. FDA approved one of the ADC in 2001 manufactured and developed by Pfizer/Wyeth, to treat acute myelogenous leukemia. The drug was subsequently withdrawn in June 2010, leaving only two antibody drug conjugates in the market. The two drugs marketed for ADCs are Brentuximab vedotin and Trastuzumab emtansine, developed and manufactured by Seattle Genetics and Millennium/Takeda and Genentech and Roche, respectively. Around 45 antibody drug conjugates molecules are under clinical trials, with the preclinical pipeline expanding at a high rate. Of all the 45 molecules, around 25% are under Phase II or Phase III of development. Frequently used cytotoxins for antibody drug conjugates under trials include auristatin, calicheamicin, maytansine and duocarmycin. Auristatin is the dominant compound accounting for over 50% of antibody drug conjugates in clinical development. Roche has 10 compounds under clinical trials, and this is the most developed pipeline of antibody drug conjugates. Globally, 70%-80% of antibody drug conjugates manufacturing is currently outsourced. There are limited number of contract manufacturers that have high-end manufacturing equipment for development of cytotoxins.
In terms of marketing, three antibody drug conjugates have received regulatory approval. The U.S. FDA approved one of the ADC in 2001 manufactured and developed by Pfizer/Wyeth, to treat acute myelogenous leukemia. The drug was subsequently withdrawn in June 2010, leaving only two antibody drug conjugates in the market. The two drugs marketed for ADCs are Brentuximab vedotin and Trastuzumab emtansine, developed and manufactured by Seattle Genetics and Millennium/Takeda and Genentech and Roche, respectively. Around 45 antibody drug conjugates molecules are under clinical trials, with the preclinical pipeline expanding at a high rate. Of all the 45 molecules, around 25% are under Phase II or Phase III of development. Frequently used cytotoxins for antibody drug conjugates under trials include auristatin, calicheamicin, maytansine and duocarmycin. Auristatin is the dominant compound accounting for over 50% of antibody drug conjugates in clinical development. Roche has 10 compounds under clinical trials, and this is the most developed pipeline of antibody drug conjugates. Globally, 70%-80% of antibody drug conjugates manufacturing is currently outsourced. There are limited number of contract manufacturers that have high-end manufacturing equipment for development of cytotoxins.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Antibody</strong> <strong>Drug</strong> <strong>Conjugates</strong> <strong>Market</strong>-<br />
GLOBAL INDUSTRY INSIGHTS, TRENDS,<br />
OUTLOOK, AND OPPORTUNITY ANALYSIS, 2016-<br />
2024<br />
© Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION<br />
<strong>Antibody</strong> <strong>Drug</strong> <strong>Conjugates</strong> <strong>Market</strong> – Overview<br />
<strong>Antibody</strong> drug conjugate is a significant class of highly potent bio drugs envisioned as a broad therapy for treatment of cancer. Unlike<br />
chemotherapy, antibody drug conjugate are proposed to mark and kill only cancer cells. <strong>Antibody</strong> drug conjugates are compound<br />
molecules that comprise antibodies linked to a biologically active cytotoxic drug.<br />
By uniting the exclusive targeting capacities of mAB with anti-cancer drugs, ADCs allow for subtle judgment between healthy and<br />
diseased tissue. This entails that the antibody drug conjugates kill only cancer cells and ensure that other dynamic cells are less severely<br />
affected. This exceptional phenomenon of killing only cancer cells increase the importance of use of ADCs, which would indirectly boost<br />
growth of the global antibody drug conjugates market.<br />
In terms of marketing, three antibody drug conjugates have received regulatory approval. The U.S. FDA approved one of the ADC in<br />
2001 manufactured and developed by Pfizer/Wyeth, to treat acute myelogenous leukemia. The drug was subsequently withdrawn in June<br />
2010, leaving only two antibody drug conjugates in the market. The two drugs marketed for ADCs are Brentuximab vedotin and<br />
Trastuzumab emtansine, developed and manufactured by Seattle Genetics and Millennium/Takeda and Genentech and Roche,<br />
respectively. Around 45 antibody drug conjugates molecules are under clinical trials, with the preclinical pipeline expanding at a high<br />
rate. Of all the 45 molecules, around 25% are under Phase II or Phase III of development. Frequently used cytotoxins for antibody drug<br />
conjugates under trials include auristatin, calicheamicin, maytansine and duocarmycin. Auristatin is the dominant compound accounting<br />
for over 50% of antibody drug conjugates in clinical development. Roche has 10 compounds under clinical trials, and this is the most<br />
developed pipeline of antibody drug conjugates. <strong>Global</strong>ly, 70%-80% of antibody drug conjugates manufacturing is currently outsourced.<br />
There are limited number of contract manufacturers that have high-end manufacturing equipment for development of cytotoxins.<br />
© Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION<br />
<strong>Global</strong> Gynecological Devices <strong>Market</strong>:<br />
Major pharmaceutical company opt for contract manufacturer for development and<br />
manufacture of antibody drug conjugates<br />
Regional segmentation of the antibody drug conjugates market by Coherent <strong>Market</strong> Insights comprises<br />
North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. Europe accounts for the<br />
largest share in the global market mainly due to presence of many contract manufacturing companies<br />
with advanced manufacturing equipment. Lonza is one of the top contract manufacturing companies in<br />
Europe, which has operations across France and Germany, with its headquarters in Switzerland. One of<br />
the facilities operated by the company is a deck to chemical manufacturing capabilities and develop<br />
peptides, small molecule active pharmaceutical ingredients, highly potent active pharmaceutical<br />
ingredients, cytotoxics agents, antibody drug conjugates, and microbial products. The company also offer<br />
proficiency in chemical, pharmaceutical, agrochemical and food industries by providing clients with yields<br />
such as high-class active substances, organic chemicals and intermediates.<br />
The global antibody drug conjugates market is segmented on the basis of drug and geography. On the<br />
basis of drug, the market is divided into Adcetris and Kadcyla.<br />
Request report sample for more professional and technical insights:<br />
https://www.coherentmarketinsights.com/insight/request-sample/181<br />
© Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION<br />
<strong>Antibody</strong> <strong>Drug</strong> <strong>Conjugates</strong> <strong>Market</strong>: Key Players<br />
Major players involved in the global antibody conjugates market include:<br />
●<br />
Hoffmann-La Roche Ltd<br />
●<br />
Seattle Genetics<br />
●<br />
Takeda<br />
●<br />
ImmunoGen Inc<br />
●<br />
Pfizer Inc.<br />
●<br />
Sanofi<br />
●<br />
AbbVie Inc<br />
●<br />
Cellldex Therapeutics<br />
●<br />
Synthon<br />
●<br />
Progenics Pharmaceuticals<br />
© Coherent market Insights. All Rights Reserved
ABOUT COHERENT MARKET INSIGHTS<br />
ABOUT US<br />
Coherent <strong>Market</strong> Insights is a global market intelligence and consulting<br />
organization focused on assisting its plethora of clients achieve transformational<br />
growth by helping them make critical business decisions. We are headquartered in<br />
India, with an office at the global financial capital in the U.S. Our client base<br />
includes players from across all business verticals in over 150 countries worldwide.<br />
We are uniquely positioned to help businesses around the globe deliver practical<br />
and lasting results through various recommendations about operational<br />
improvements, technologies, emerging market trends and new working methods.<br />
We offer both customized and syndicated market research reports that help our<br />
clients create visionary growth plans to provide traction to their business. We<br />
meticulously study emerging trends across various industries at both the global<br />
and regional levels to identify new opportunities for our clientele.<br />
SERVICES<br />
INDUSTRY ANALYSIS<br />
MARKET INTELLIGENCE<br />
SERVICES<br />
CUSTOMIZED<br />
RESEARCH<br />
CONSULT STUDIES<br />
SYNDICATED RESEARCH<br />
COUNTRY SPECIFIC<br />
STUDIES<br />
© Coherent market Insights. All Rights Reserved
ABOUT COHERENT MARKET INSIGHTS<br />
Industries we cater<br />
SECTOR COVERAGE<br />
Healthcare<br />
BIOTECHNOLOGY CLINICAL DIAGNOSTIC HEALTHCARE IT<br />
MEDICAL DEVICES<br />
MEDICAL IMAGING<br />
Chemicals & Materials<br />
PHARMACEUTICAL<br />
Bulk Chemicals Advanced Materials Speciality and Fine<br />
Chemicals<br />
Green Chemicals<br />
Food Ingredients<br />
Cosmetic<br />
Ingredients<br />
Polymers &<br />
Resins<br />
© Coherent market Insights. All Rights Reserved
ABOUT COHERENT MARKET INSIGHTS<br />
KEY STATS<br />
100+<br />
Insights Published Per Year<br />
150+<br />
Consulting Projects Till Date<br />
125+<br />
Clients Worldwide Per Year<br />
RESEARCH SOLUTIONS<br />
CONSULT<br />
PROJECTS<br />
SURVEY<br />
RESEAR<br />
CH<br />
FEASIBILITY<br />
STUDIES<br />
EXCEL<br />
FORECAST<br />
DATABASE<br />
GLOBAL<br />
REPORTS<br />
COUNTRY<br />
ANALYSIS<br />
CUSTOMIZED<br />
SOLUTIONS<br />
COMPETITIVE<br />
ASSESSMENT<br />
110+<br />
Analysts and Contract Consultants<br />
TECHNOLOGY<br />
SNIPPETS<br />
Coherent <strong>Market</strong> Insights excels at offering unmatched actionable market intelligence across various industry verticals, including<br />
chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in<br />
the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various<br />
industries<strong>—</strong>no matter how large or small, how complex or unique<strong>—</strong>we help our clients achieve better outcomes with uniquely<br />
designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed<br />
markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein.<br />
© Coherent market Insights. All Rights Reserved
THANK YOU<br />
To know more about us, visit our website:<br />
www.coherentmarketinsights.com<br />
For sales queries or new topics email us on:<br />
sales@coherentmarketinsights.com<br />
For other queries contact:<br />
Mr. Shah<br />
(Manager - Business Development)<br />
Coherent <strong>Market</strong> Insights<br />
sales@coherentmarketinsights.com<br />
+1-206-701-6702<br />
© Coherent market Insights. All Rights Reserved
Change language